• Login
    • Library Home
    View Item 
    •   BracU IR
    • School of Pharmacy (PHR)
    • Bachelor of Pharmacy
    • Project report (Bachelor of Pharmacy)
    • View Item
    •   BracU IR
    • School of Pharmacy (PHR)
    • Bachelor of Pharmacy
    • Project report (Bachelor of Pharmacy)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease

    Thumbnail
    View/Open
    13146070_PHR.pdf (1.401Mb)
    Date
    2018-08
    Publisher
    BRAC University
    Author
    Haque, Mushfiqul
    Metadata
    Show full item record
    URI
    http://hdl.handle.net/10361/11070
    Abstract
    Alzheimer’s disease (AD), a deadly neurodegenerative disease, which is considered as one of the top causes of death for people who are over 65 years of age. Up until now, no drug has been developed that can cure this disease but a number of drugs have been developed that can modify the disease condition. Currently, cholinesterase inhibitors – tacrine, donepezil, rivastigmine, galantamine and NMDA antagonist – memantine are approved for the treatment of Alzheimer’s disease. We reviewed the evidences behind efficacy and safety of these drugs by searching journal articles from Embase, PubMed and Google Scholar. We used placebo controlled trials and comparative trials for this purpose. Moreover, we also compared the costs of treatment with these drugs. Review of the articles suggested that cholinesterase inhibitors have positive effects in improving cognition and behavior and that there is no statistically significant difference between the efficacy cholinesterase inhibitors in treating mild to moderate Alzheimer’s disease. Donepezil has been found to have lowest incidences of adverse drug events and highest for tacrine. On the other hand, memantine has been found to improve not only cognitive functions but also to prevent further neurodegeneration in moderate to severe AD patients. It has great beneficial effects on Severe Impairment Battery (SIB) scores and also on Alzheimer’s disease Cooperative Study – Activities of Daily Living (ADCS-ADL). In terms of adverse drug events, studies have suggested that memantine has moderate safety and tolerability. Another strategy for managing AD is the combination therapy of cholinesterase inhibitors and memantine. It is efficacious in managing moderate to severe AD and does not cause higher incidences of adverse events in comparison to treatment where cholinesterase inhibitor is used alone. Comparison of costs of drugs, have suggested donepezil to be better choice for treatment of mild to moderate AD and memantine for moderate to severe AD.
    Keywords
    Alzheimer’s disease; Cholinesterase inhibitors; NMDA antagonists; Combination therapy; Efficacy; Cost effectiveness
     
    Description
    This project report is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2018.
     
    Catalogued from PDF version of project report.
     
    Includes bibliographical references (page 55-66).
    Department
    Department of Pharmacy, BRAC University
    Collections
    • Project report (Bachelor of Pharmacy)

    Copyright © 2008-2019 Ayesha Abed Library, Brac University 
    Contact Us | Send Feedback
     

     

    Policy Guidelines

    • BracU Policy
    • Publisher Policy

    Browse

    All of BracU Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Copyright © 2008-2019 Ayesha Abed Library, Brac University 
    Contact Us | Send Feedback